Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control?
LIPSKA K, PARKER M, MOFFET H, HUANG E, KARTER A. Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control? Diabetes 2018, 67 DOI: 10.2337/db18-1311-p.Peer-Reviewed Original ResearchNeutral protamine HagedornType 2 diabetesReal-world clinical practiceSevere hypoglycemiaGlycemic controlInsulin analoguesClinical practiceKaiser Permanente Northern CaliforniaDiabetes medication useInsulin analogue useBasal insulin analoguesClinical trial populationsType of insulinHealth plan coverageHazard ratioInsulin initiationNPH insulinPatient characteristicsBasal insulinHemoglobin A1cMedication useSulfonylurea treatmentTrial populationHypoglycemic eventsNocturnal hypoglycemiaHigh-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions
MCCOY R, HOUTEN H, LIPSKA K, SHAH N. High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1652-p.Peer-Reviewed Original ResearchEnd-stage renal diseaseChronic kidney diseaseChronic obstructive pulmonary diseaseMajority of patientsHeart failureMyocardial infarctionSerious comorbiditiesGlycemic controlCerebrovascular diseaseChronic conditionsHigh-risk medication usePlurality of patientsProportion of patientsObstructive pulmonary diseaseStage renal diseaseUse of insulinOptumLabs Data WarehouseTight glycemic controlHigh-risk drugsSerious chronic conditionsMedicare Advantage beneficiariesGlycemic targetsUrinary incontinenceMedication usePeripheral neuropathy